2010 Annual Scientific Meeting and Exposition 2010 Annual ...

in hypertensionMany hypertensive patients could benefit from a more comprehensiveRAAS inhibitor than an ARB to help achieve their BP goals 1-3A SMART VALTURNATIVEVisit Booth #1100to learn more about VALTURNAIndicationVALTURNA is indicated for the treatment of hypertension in adults.VALTURNA may be substituted for the titrated components. VALTURNA may be used inpatients whose blood pressure is not adequately controlled on aliskiren or any ARBmonotherapy and as initial therapy in patients who are likely to need multiplemedications to achieve their blood pressure goals.The choice of VALTURNA as initial therapy should be based on an assessment of potentialbenefits and risks. The decision to use a combination as initial therapy should beindividualized and should be shaped by considerations such as baseline blood pressure,target goal, and the incremental likelihood of achieving goal with a combination productcompared to monotherapy.Important Safety InformationWARNING: AVOID USE IN PREGNANCY: When pregnancy is detected, discontinueVALTURNA as soon as possible. When used in pregnancy during the second and thirdtrimesters, drugs that act directly on the renin-angiotensin-aldosterone system (RAAS)can cause injury and even death to the developing fetus. [See Warnings andPrecautions (5.1)]Angioedema: Angioedema of the face, extremities, lips, tongue, glottis, and/or larynx hasbeen reported in patients treated with aliskiren and has necessitated hospitalization andintubation. This may occur at any time during treatment and has occurred in patients withand without a history of angioedema with ACE inhibitors (ACEIs) or angiotensin receptorantagonists. Discontinue aliskiren immediately in patients who develop angioedema, andprovide appropriate therapy and monitoring until signs and symptoms resolve. Aliskirenshould not be readministered.Hypotension: In clinical trials, an excessive fall in blood pressure (hypotension) was seen rarely(